238 related articles for article (PubMed ID: 18991753)
1. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
Cerecetto H; González M
Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
3. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
4. Research for new antichagasic drugs.
Mester B; Claramunt RM; Elguero J; Atienza J; Gómez Barrio A; Escario JA
Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):1990-3. PubMed ID: 1797419
[TBL] [Abstract][Full Text] [Related]
5. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
[TBL] [Abstract][Full Text] [Related]
6. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
7. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
8. Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease.
Salas CO; Faúndez M; Morello A; Maya JD; Tapia RA
Curr Med Chem; 2011; 18(1):144-61. PubMed ID: 21110810
[TBL] [Abstract][Full Text] [Related]
9. An insight on targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG; Couto AS
Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):19-51. PubMed ID: 18221162
[TBL] [Abstract][Full Text] [Related]
10. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Wilkinson SR; Kaiser M
Eur J Med Chem; 2014 Nov; 87():79-88. PubMed ID: 25240098
[TBL] [Abstract][Full Text] [Related]
11. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
[TBL] [Abstract][Full Text] [Related]
12. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
13. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects of anti-Trypanosoma cruzi compounds on HSP60 levels.
Muelas-Serrano S; Pérez-Serrano J; Gómez-Barrio A; Ochoa C; Martínez J; Rodríguez-Caabeiro F
Parasitol Res; 2001 Aug; 87(8):615-8. PubMed ID: 11510996
[TBL] [Abstract][Full Text] [Related]
15. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
Menna-Barreto RF; de Castro SL
Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
[TBL] [Abstract][Full Text] [Related]
16. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
[TBL] [Abstract][Full Text] [Related]
17. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
18. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
19. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
[TBL] [Abstract][Full Text] [Related]
20. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
